Avexitide for glucose metabolism disorders

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Trial registered. A trial in people is registered. As of 19 Nov 2026, from 1 registered trial.

Also followed for narrower conditions: Hypoglycemia

Why this status

  1. 13 May 2016: Trial registered, NCT02771574

The trials

NCT02771574: Efficacy, Tolerability and Pharmacokinetics of Subcutaneous Exendin (9-39) in Patients With Post Bariatric Hypoglycemia

State
Completed
Phase
Phase 2
People
19 taking part
Started
May 2016
Primary completion
Jun 2017
Arms
Part A: Lyo avexitide 0.05 mg/kg, Part A: Lyo avexitide 0.15 mg/kg, Part A: Lyo avexitide 0.35 mg/kg, Part A: Lyo avexitide 0.46 mg/kg, Part B: Liq avexitide 0.38 (±0.03) mg/kg
Results
Posted on the registry
  1. 13 May 2016: Trial registered
  2. 14 Aug 2020: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Trial registered

About the treatment

Kind of treatment: Drug.

Also known as Liq avexitide, Lyo avexitide, exendin -(9-39), exendin 9-39, exendin-(9-39).

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.